Avience Biomedicals Ltd vs Clinitech Laboratory Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Avience Biomedicals Ltd is ₹ 240 as of 23 Oct 15:30 . The P/E Ratio of Avience Biomedicals Ltd is 0 as of March 2025 .The P/E Ratio of Clinitech Laboratory Ltd is 23.3 as of March 2025 . The Market Cap of Avience Biomedicals Ltd is ₹ 0 crore as of March 2025 .The Market Cap of Clinitech Laboratory Ltd is ₹ 9.18 crore as of March 2025 . The Dividend Payout of Avience Biomedicals Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Clinitech Laboratory Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Avience Biomedicals Ltd

Avience Biomedicals Limited was originally incorporated as Private Limited Company as 'Avience Biomedicals Private Limited' on December 23, 2019 with the Registrar of Companies, Delhi.
Later, Company's status got converted into a Public Limited Company, the name of the Company was changed to 'Avience Biomedicals Limited' and fresh Certificate of incorporation dated September 3, 2024, was issued by the Registrar of Companies, Delhi. Avience Biomedicals Limited is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices in Noida, Uttar Pradesh, India.
In vitro diagnostics (IVDs) are tests that can detect disease, conditions and infections. The Company commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, Human Immunodeficiency Viruses (HIV), HBs AG, Malaria, Dengue and others aimed at aiding medical institutions with affordable and good-quality solutions.

About Clinitech Laboratory Ltd

Clinitech Laboratory Limited was incorporated as Clinitech Laboratory Private Limited on March 19, 2010 with the Registrar of Companies, Mumbai.
The status of Company was changed to Public Limited and the name of Company changed to Clinitech Laboratory Limited through fresh certificate of incorporation upon conversion on August 25, 2023 was issued by the Registrar of Companies, Mumbai.
Company is in the business of healthcare services providing superior quality services such as pathology testing laboratories, diagnostic centers, scan centers, X-ray and ECG clinics, etc. The Company established a new Lab in Kalyan in 2012, NABL Accreditation at Airoli Centre in 2016, a new Lab at Thane in 2018.
Besides these, the Company conduct more than 150 tests including Biochemistry, Immunology, Hematology, Molecular Biology tests, urine analysis, Serology, Microbiology and Histopathology tests.

FAQs for the comparison of Avience Biomedicals Ltd and Clinitech Laboratory Ltd

Which company has a larger market capitalization, Avience Biomedicals Ltd or Clinitech Laboratory Ltd?

Market cap of Avience Biomedicals Ltd is 131 Cr while Market cap of Clinitech Laboratory Ltd is 7 Cr

What are the key factors driving the stock performance of Avience Biomedicals Ltd and Clinitech Laboratory Ltd?

The stock performance of Avience Biomedicals Ltd and Clinitech Laboratory Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Avience Biomedicals Ltd and Clinitech Laboratory Ltd?

As of October 25, 2026, the Avience Biomedicals Ltd stock price is INR ₹240.0. On the other hand, Clinitech Laboratory Ltd stock price is INR ₹32.0.

How do dividend payouts of Avience Biomedicals Ltd and Clinitech Laboratory Ltd compare?

To compare the dividend payouts of Avience Biomedicals Ltd and Clinitech Laboratory Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.